Marius Militaru

Dr. Marius Militaru

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Marius MilitaruMarius Militaru
Marius Militaru
Daniel Florin LighezanDaniel Florin Lighezan
Daniel Florin Lighezan
Cristina TudoranCristina Tudoran
Cristina Tudoran
AMAnda Gabriela Militaru
Anda Gabriela Militaru
(1) Background: Cognitive decline (CD), considered a precursory state of dementia, is frequently encountered in patients with diabetes mellitus type 2 (DM-2) and might even have a higher prevalence in those with associated atrial fibrillation (AF). In this study, we aimed to research if the association of DM-2 and AF favors a precocious onset of CD. (2) Methods: This study was conducted on 160 patients, featuring 50 with DM-2, 54 with DM-2 and AF, and 56 subjects without DM-2 and AF, all evaluated clinically and with five neuropsychiatric scales. (3) Results: The Mini-Mental-State-Examination (MMSE), Montreal Cognitive Assessment (MoCA), Activities of Daily Living Score (ADL), Instrumental Activities of Daily Living Score (IADL), and Geriatric Depression Scale (GDS-15) were significantly altered in patients with DM-2 and AF in comparison to patients without these diseases. The logistic regression model indicated that, in patients with DM-2 and AF, an increase of one year in age is associated with a 7.3% augmentation of the risk of a precocious onset of CD (MMSE < 27). (4) Conclusions: CD is more frequent in patients with DM-2, especially when associated with AF, versus those without DM-2 and AF. Our findings suggest that an older age and associated dyslipidemia represent risk factors for CD in patients with DM-2.

6 June 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Marius MilitaruMarius Militaru
Marius Militaru
CRCiprian Rachieru
Ciprian Rachieru
Daniel Florin LighezanDaniel Florin Lighezan
Daniel Florin Lighezan
AMAnda Gabriela Militaru
Anda Gabriela Militaru
Background: Assessment of cognitive impairment and the presence of subclinical atherosclerosis are very important especially in patients with cardiovascular risk factors. Methods: We included 155 hypertensive patients (84 with AF versus 71 without AF) to identify the premature cognitive impairment, the earliest signs of subclinical atherosclerosis and onset of myocardial dysfunction and to evaluate the type of anticoagulation used, the importance of CHA₂DS₂-VASc score (3), age (65 years) in hypertensive patients with AF. Results: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment Scale (MoCA), Left Ventricular Ejection Fraction (LVEF) were significantly decreased, and Activities of Daily Living Score (ADL), Geriatric Depression Scale(GDS-15), and intima–media thickness (IMT) were significantly increased in hypertensive patients with AF vs. without AF (p < 0.05). MMSE was significantly decreased, ADL and IMT were significant increased in patients with AF and CHA₂DS₂-VASc>3 and non-vitamin K antagonists oral anticoagulants therapy (NOACs)(p < 0.05). Patients with age >65 with AF had higher rates of cognitive impairment (MMSE significant decrease) and a larger IMT (significant increase) versus patients with AF and age <65 (p < 0.05). Conclusions: Cognitive impairment is encountered in hypertensive patients having AF. Our conclusions suggest a direct link between cognitive impairment, depression, hypertension, AF, age, CHA₂DS₂-VASc score, type of anticoagulants used, LVEF, cognitive parameters, and IMT. We acknowledge the importance of identifying and preventing cognitive changes.

Verified
Journal Article
Open access
PDF file
VNVHAROON SHARMA NUNKOO
VHAROON SHARMA NUNKOO
AJAnamaria Jurcau
Anamaria Jurcau
MLMihaela Les
Mihaela Les
ACAlexander Cristian
Alexander Cristian
Marius MilitaruMarius Militaru
Marius Militaru
MJMaria Carolina Jurcau
Maria Carolina Jurcau
With a rapidly growing incidence and prevalence, Alzheimer’s disease (AD) is rapidly becoming one of the most disabling, lethal, and expensive diseases of the century. To diagnose AD as early as possible, the scientific world struggles to find reliable and non-invasive biomarkers that could predict the conversion of mild cognitive impairment to AD and delineate the ongoing pathogenic vicious pathways to be targeted with therapy. Research supports the use of blood biomarkers, such as Aβ1-42/Aβ1-40 ratio, phosphorylated tau181, and p-tau217 for diagnostic purposes, although the cut-offs are not clearly established and can depend on the assays used. For more accurate diagnosis, markers of neurodegeneration (neurofilament light) and neuroinflammation (glial fibrillary acidic protein) could be introduced in the biomarker panel. The recent approval of the Lumipulse G p-tau217/Aβ1-42 plasma ratio by the FDA for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs and symptoms of the disease represents a significant advancement in the diagnosis of Alzheimer’s disease, offering a more accessible and less invasive way to diagnose this devastating disease and allow potentially earlier access to treatment options.

29 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMaria Alina Marin
Maria Alina Marin
RCRaluca Maria Cloșca
Raluca Maria Cloșca
AMAurel Marin
Aurel Marin
MRMarina Rakitovan
Marina Rakitovan
ANAdrian Nicoara
Adrian Nicoara
Flavia BadercaFlavia Baderca
Flavia Baderca
Nasopharyngeal carcinoma is one of the most common malignant tumors in the head and neck region. The carcinogenesis is a complex process stimulated by many factors. Although the etiological factors and pathogenic mechanisms are not elucidated, the genetic susceptibility, environmental factors, and association with latent infection with Epstein–Barr Virus play an important role. The aim of this study was to present the main clinical and epidemiological data, as well as the morphological aspects and the immunohistochemical profile, of patients with nasopharyngeal carcinoma diagnosed in western Romania. The study was retrospective and included 36 nasopharyngeal carcinomas. The histopathological diagnosis was completed using immunohistochemical reactions for the following antibodies: p63, p53 and p16 protein, cytokeratins (CK) AE1/AE3, CK5, CK7, CK20 and 34βE12, epithelial membrane antigen (EMA), Epstein–Barr virus (EBV), leukocyte common antigen (LCA), CD20, CD4, CD8, CD68, CD117, and CD1a. The squamous malignant component of nasopharyngeal carcinoma presented with positivity for cytokeratins AE1/AE3, CK5, 34βE12, and p63. Undifferentiated nasopharyngeal carcinoma was positive for EMA in 67% of cases, and 28% of cases showed an immunoreaction for CD117 in the malignant epithelial component. Also, the p53 protein was positive in all the cases. One case of undifferentiated nasopharyngeal carcinoma was p16-positive, and two cases were positive for EBV. A peri- and intratumor cellular infiltrate rich in lymphocytes, with a predominance of CD20-positive B lymphocytes, interspersed with T lymphocytes, was observed. The T cells were CD4- and CD8-positive, predominantly intratumoral, and the CD4:CD8 ratio was 1:1 for 75% of the undifferentiated subtype and 89% for differentiated non-keratinized squamous cell carcinoma. All subtypes of nasopharyngeal carcinoma presented with an inflammatory infiltrate with numerous plasma cells, eosinophils, and dendritic cells, presenting as antigen CD1a- and CD68-positive, as well as in CD117-positive mast cells.

13 November 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Marius MilitaruMarius Militaru
Marius Militaru
Daniel Florin LighezanDaniel Florin Lighezan
Daniel Florin Lighezan
Cristina TudoranCristina Tudoran
Cristina Tudoran
MTMARIANA TUDORAN
MARIANA TUDORAN
AMAnda Gabriela Militaru
Anda Gabriela Militaru
Background and Objectives: Considering the increasing prevalence of chronic heart failure (CHF) and cognitive decline (CD) observed in recent decades and the complex interrelation between these two pathologies often encountered in the same patient, in this study, we aimed to highlight the connection between CHF, defined as recommended by the European Society of Cardiology guidelines, and CD, evaluated by employing five neuropsychological scales. Materials and Methods: Our study was conducted on 190 patients with very high cardiovascular risk profiles admitted between 5 September 2021 and 15 November 2023 in the Municipal Emergency Hospital Timisoara. Of these, 103 had CHF (group A) and 87 did not (group B). Results: Although similar concerning age, sex distribution, and risk factors (excepting lipid profile), patients from group A had lower Mini Mental State Evaluation (MMSE) and Montreal Cognitive Assessment (MoCA levels (p = 0.003, respectively, p = 0.017) scores, more reduced daily activity (p = 0.021), and more severe depression (p = 0.015) compared to group B. We documented statistically significant correlations between left-ventricular ejection fraction (LVEF) and the levels of N-terminal pro–B-type natriuretic peptide (NT-pro-BNP), as well as with the results of MMSE (r = 0.226, p = 0.002 and r = −0.275, p = 0.005, respectively), daily activity, and depression (p ˂ 0.001). Multi-logistic regression models indicated age, blood pressure values, decreased daily activity, and depression as risk factors for CD in patients with CHF. Conclusions: In patients with CHF, there is an increased propensity of CD, with a direct relationship between MMSE and LVEF levels and an indirect one between MMSE and NT-pro-BNP levels. The concomitance of depression and reduced activity levels are aggravating CD in these patients.

Verified
Journal Article
Open access
PDF file
Daian Ionel PopaDaian Ionel Popa
Daian Ionel Popa
BFBuleu Florina
Buleu Florina
IAIancu Aida
Iancu Aida
ATAnca Tudor
Anca Tudor
CWCarmen Gabriela Williams
Carmen Gabriela Williams
Mederle Alexandru OvidiuMederle Alexandru Ovidiu
Mederle Alexandru Ovidiu
Background: Rapid identification and treatment of stroke are essential for the patient. Our objective was to determine the diagnostic utility of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in the emergency department to identify and differentiate acute stroke within 4.5 h of symptom onset in patients admitted with a stroke code alert. Methods: This study included 85 patients with a “code stroke alert” upon arrival at the emergency department. Individuals were grouped in two categories: patients with stroke (including 69 patients) and patients without stroke (including 16 patients). The research was conducted at the Emergency Municipal Clinical Hospital in Timișoara, Romania, the county’s second-largest hospital, which lacks a neurologist and a dedicated stroke unit. Results: No significant differences were observed between the two groups (with stroke and without stroke) regarding most demographic or admission parameters. Significant differences were observed for the biomarkers GFAP (142.91 ± 102.19 pg/mL in patients with acute stroke vs. 37.76 ± 19.92 pg/mL in patients without stroke (p < 0.001)) and UCH-L1 (1307.68 ± 967.54 pg/mL in stroke patients vs. 189.81 ± 92.69 pg/mL in patients without stroke (p < 0.001)). Within the stroke group, 37 patients had acute ischemic stroke, while 32 patients were diagnosed with hemorrhagic stroke based on brain CT imaging. GFAP achieved an accuracy of 94.2% for differentiating hemorrhagic from ischemic stroke, with a cut-off value of 77.15 pg/mL. Conclusions: GFAP excellently differentiated acute stroke from stroke mimics, with high sensitivity, perfect specificity, and strong predictive values. Integrating GFAP and UCH-L1 measurements into emergency protocols may enhance stroke diagnosis, optimize patient triage, and ultimately improve outcomes by facilitating the faster initiation of appropriate therapies.